Amneal Pharmaceuticals, Inc.
Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
About
CEO
Mr. Chirag K. Patel
Employees
7,850
Instrument type
Common Stock
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
MIC code
XNGS
Address
400 Crossing Boulevard, Bridgewater, NJ 08807, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Mar 13, 2025 | 0.16 | — | — | — |
| Feb 28, 2025 | 0.16 | — | — | — |
| Nov 8, 2024 | 0.14 | 0.16 | 0.02 | 14.29% |
| Aug 9, 2024 | 0.14 | 0.16 | 0.02 | 14.29% |
| May 3, 2024 | 0.09 | 0.14 | 0.05 | 55.56% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 4 |
| Average estimate | — | 0.17 | — | 0.73 |
| Low estimate | — | 0.14 | — | 0.58 |
| High estimate | — | 0.21 | — | 0.81 |
| Last year EPS | — | 0.14 | — | 0.61 |
[stock_revenue_estimate]
Growth estimates
Current qtr
9.730%
Next qtr. (Mar 2025)
21.660%
Current year
-4.090%
Next year (Dec 2025)
18.510%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 2.39B | 2.21B | 2.09B | 1.99B | 1.63B |
| Cost of revenue | 1.57B | 1.43B | 1.32B | 1.36B | 1.27B |
| Gross profit | 820.57M | 784.71M | 768.97M | 628.39M | 353.00M |
| Operating expense | |||||
| Research & development | 167.78M | 200.05M | 209.56M | 190.59M | 202.29M |
| Selling general and admin | 429.68M | 399.70M | 365.50M | 326.73M | 289.60M |
| Other operating expenses | -1.14M | -3.96M | — | — | — |
| Operating income | 224.25M | 188.92M | 193.91M | 111.08M | -138.89M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 210.63M | 158.38M | 136.33M | 146.00M | 168.21M |
| Other income expense | -13.09M | -278.38M | -26.22M | -863,000 | 86.85M |
| Pretax income | -40.27M | -248.13M | 31.37M | -35.78M | -220.24M |
| Tax provision | 8.45M | 6.66M | 11.20M | -104.36M | 383.33M |
| Net income | -48.72M | -254.79M | 20.17M | 68.58M | -603.57M |
| Basic EPS | -0.48 | -0.86 | 0.07 | 0.62 | -2.74 |
| Diluted EPS | -0.48 | -0.86 | 0.07 | 0.61 | -2.74 |
| Basic average shares | 176.14M | 150.94M | 148.92M | 147.44M | 132.11M |
| Diluted average shares | 176.14M | 150.94M | 148.92M | 147.44M | 132.11M |
| EBITDA | 417.96M | 446.64M | 442.64M | 349.06M | 69.81M |
| Net income from continuing op. | -48.72M | -254.79M | 20.17M | 68.58M | -603.57M |
| Minority interests | -35.27M | 124.80M | -9.55M | 22.48M | 241.66M |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3.47B | 3.80B | 3.94B | 4.01B | 3.67B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 91.54M | 25.98M | 247.79M | 341.38M | 151.20M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 613.73M | 741.79M | 662.58M | 638.90M | 604.39M |
| Other receivables | 17.81M | 41.74M | 22.13M | 22.03M | 16.00M |
| Inventory | 581.38M | 530.74M | 489.39M | 490.65M | 381.07M |
| Prepaid assets | 51.71M | 48.95M | 46.24M | 39.56M | 40.43M |
| Restricted cash | 7.57M | 9.25M | 41.95M | 5.74M | 1.63M |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | — | — | — |
| Non current assets | |||||
| Properties | 102.56M | 119.55M | 124.85M | 126.96M | 142.60M |
| Land and improvements | 9.02M | 10.71M | 11.54M | 4.94M | 4.39M |
| Machinery furniture equipment | 524.61M | 485.44M | 484.42M | 414.68M | 378.64M |
| Construction in progress | 67.67M | 69.34M | 58.26M | 71.46M | 64.40M |
| Leases | 126.46M | 124.67M | 123.51M | 108.70M | 103.19M |
| Accumulated depreciation | -508.03M | -445.97M | -394.56M | -332.14M | -276.05M |
| Goodwill | 2.09B | 2.29B | 2.35B | 2.35B | 2.22B |
| Investment properties | — | — | — | — | — |
| Financial assets | 37.09M | 85.59M | — | — | 16.37M |
| Intangible assets | 890.42M | 1.10B | 1.17B | 1.30B | 1.38B |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 11.55M | 10.40M | 10.82M | 9.51M | 8.08M |
| Total liabilities | 3.45B | 3.62B | 3.57B | 3.66B | 3.32B |
| Current liabilities | |||||
| Accounts payable | 143.57M | 165.98M | 131.08M | 153.14M | 103.02M |
| Accrued expenses | 309.74M | 307.96M | 319.41M | 384.04M | 349.50M |
| Short term debt | 227.62M | 104.64M | 46.04M | 57.47M | 36.95M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | 359,000 | 2.52M | 5.54M | 8.73M |
| Pensions | 71.12M | 54.04M | 62.10M | 58.92M | 36.01M |
| Other current liabilities | 76.99M | 107.48M | 58.00M | — | — |
| Non current liabilities | |||||
| Long term debt | 2.52B | 2.74B | 2.83B | 2.89B | 2.73B |
| Provision for risks and charges | 497,000 | 563,000 | 3.18M | 3.07M | 5.09M |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | 11.47M | 53.90M | — |
| Other non current liabilities | 8.22M | 70.17M | 2.66M | 5.86M | 7.89M |
| Shareholders equity | |||||
| Common stock | 3.07M | 3.04M | 3.01M | 3.00M | 2.99M |
| Retained earnings | -490.18M | -406.18M | -276.20M | -286.82M | -377.88M |
| Other shareholders equity | -32.35M | 9.94M | -24.83M | -41.32M | -68,000 |
| Total shareholders equity | 20.01M | 183.98M | 366.97M | 344.93M | 346.79M |
| Additional paid in capital | 539.24M | 691.63M | 658.35M | 628.41M | 606.97M |
| Treasury stock | — | — | — | — | — |
| Minority interest | 230,000 | -114.44M | 6.63M | 41.66M | 114.78M |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -48.72M | -254.79M | 20.17M | 68.58M | -603.57M | -201.30M | 169.33M | 209.43M |
| Depreciation | 229.40M | 240.18M | 233.41M | 235.39M | 207.24M | 137.40M | 45.94M | 33.02M |
| Deferred Taxes | — | — | — | — | 371.72M | -9.44M | 742,000 | 121,000 |
| Stock-Based Compensation | 26.82M | 31.85M | 28.41M | 20.75M | 21.68M | 167.60M | — | — |
| Other Non-Cash Items | 44.41M | 17.45M | 15.19M | 19.96M | -130.25M | 24.05M | 14.52M | 3.25M |
| Accounts Receivable | 125.80M | -79.07M | -16.31M | 17.20M | -133.67M | 100.01M | 29.77M | -122.18M |
| Accounts Payable | -94.45M | 109.57M | -43.93M | 307,000 | -10.26M | -53.55M | 18.11M | 6.27M |
| Other Assets & Liabilities | -126.18M | -102.40M | -49.02M | -113.78M | -20.39M | -42.02M | -31.83M | -42.59M |
| Operating Cash Flow | 157.08M | -37.22M | 187.92M | 248.40M | -297.50M | 122.75M | 246.57M | 87.32M |
| Investing Activities | ||||||||
| Capital Expenditures | -46.80M | -48.80M | -50.94M | -61.84M | -47.18M | -57.74M | -94.77M | -122.76M |
| Net Intangibles | -22.39M | -41.80M | -1.70M | -4.35M | -50.25M | -14.00M | -19.50M | -1.85M |
| Net Acquisitions | — | -84.71M | -146.54M | -251.36M | 34.83M | -324.63M | 15.72M | — |
| Purchase of Investments | — | — | — | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — |
| Investing Cash Flow | -46.80M | -132.51M | -192.48M | -313.20M | 30.67M | -382.38M | -79.05M | -122.76M |
| Financing Activities | ||||||||
| Long-Term Debt Issuance | 217.73M | — | — | 180.00M | — | 1.33B | 300.00M | 225.00M |
| Long-Term Debt Payments | -414.08M | -123.27M | -79.18M | -37.01M | -29.27M | -784.34M | -13.90M | -36.40M |
| Other Financing Charges | -235.68M | -69.01M | -59.80M | -11.50M | -17.96M | -74.17M | -5.85M | -7.48M |
| Financing Cash Flow | -213.02M | -107.28M | -138.98M | 131.49M | -47.23M | 191.84M | -95.02M | -19.50M |
| Other Cash Details | ||||||||
| End Cash Position | 99.11M | 35.23M | 256.74M | 347.12M | 152.82M | 218.78M | 77.92M | 37.55M |
| Income Tax Paid | 2.50M | 12.65M | 15.56M | — | 10.26M | 34.95M | — | — |
| Interest Paid | 192.81M | 142.72M | 121.75M | 130.19M | 158.57M | 131.51M | 65.09M | 50.57M |
| Free Cash Flow | 276.39M | -25.50M | 189.18M | 312.82M | -95.73M | 153.14M | 119.92M | -9.55M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Russell 2000 ETF | Nov 30, 2024 | 4,508,577 | 35.98M | 1.47% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 4,357,263 | 34.77M | 1.42% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 3,491,925 | 27.87M | 1.14% |
| Vanguard Small Cap Value Index Fund | Sep 30, 2024 | 2,360,429 | 18.84M | 0.77% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 2,162,272 | 17.25M | 0.71% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 1,618,229 | 12.91M | 0.53% |
| Hennessy Cornerstone Growth Fund | Oct 31, 2024 | 1,583,500 | 12.64M | 0.52% |
| College Retirement Equities Fund-Stock Account | Sep 30, 2024 | 1,314,150 | 10.49M | 0.43% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 1,209,998 | 9.66M | 0.39% |
| Columbia Fds Ser Tr-Columbia Small Cap Value II Fd | Nov 30, 2024 | 1,132,730 | 9.04M | 0.37% |
Article
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Feb 6, 2025
Article
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know
The consensus price target hints at a 27.1% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Feb 3, 2025
Article
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
Jan 31, 2025
